Pharma M&A versus alliances and its underlying value drivers

Are M&A or alliances the right therapy for an ailing pharmaceutical industry?- A capital market perspective

Serie: Corporate Finance and Governance 15

From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. Les mer
Vår pris
526,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 7 virkedager
På grunn av Brexit-tilpasninger og tiltak for å begrense covid-19 kan det dessverre oppstå forsinket levering.

Innbundet
Legg i
Innbundet
Legg i
Vår pris: 526,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 7 virkedager
På grunn av Brexit-tilpasninger og tiltak for å begrense covid-19 kan det dessverre oppstå forsinket levering.

Om boka

From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story? The author derives significant innovative determinants of success for both strategies.

Fakta

Innholdsfortegnelse

Contents: The Pharmaceutical Industry and its Paradigm Shift - The Pharmaceutical Industry and Mergers & Acquisitions - Value Creation in Pharmaceutical M&A and its underlying Value Drivers - The Pharmaceutical Industry and Alliances - Value Creation in Pharmaceutical In-licensings and its underlying Value Drivers - M&A versus In-licensing.

Om forfatteren

Heiko Schoen studied international business administration at Wiesbaden Business School. He was scholar of the German National Merit Foundation (sdw), he owns an Executive MBA from the University of Munster and earned his PhD at the University of Darmstadt. He brings in 10 years of experience in the pharmaceutical and chemical industry.